Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

2025 Annual Meeting of Stockholders

Jun 13, 2025 • 10:00am EDT

First Quarter 2025 Earnings Call

May 13, 2025 • 8:30am EDT